HIGH TIDE INC (HITI) Stock Fundamental Analysis
USA - NASDAQ:HITI - CA42981E4013 - Common Stock
3.01 USD
+0.01 (+0.33%)
3 USD
-0.01 (-0.33%)
Taking everything into account, HITI scores 4 out of 10 in our fundamental rating. HITI was compared to 192 industry peers in the Pharmaceuticals industry. The financial health of HITI is average, but there are quite some concerns on its profitability. HITI has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
HITI had negative earnings in the past year.
In the past year HITI had a positive cash flow from operations.
In the past 5 years HITI always reported negative net income.
HITI had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
HITI's Return On Assets of -3.76% is fine compared to the rest of the industry. HITI outperforms 73.96% of its industry peers.
HITI has a Return On Equity of -6.93%. This is in the better half of the industry: HITI outperforms 76.04% of its industry peers.
The Return On Invested Capital of HITI (5.06%) is better than 82.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.76% | ||
| ROE | -6.93% | ||
| ROIC | 5.06% |
ROA(3y)-14.91%
ROA(5y)-13.84%
ROE(3y)-26.27%
ROE(5y)-34.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Operating Margin value of 2.30%, HITI is doing good in the industry, outperforming 79.17% of the companies in the same industry.
HITI's Gross Margin of 25.83% is in line compared to the rest of the industry. HITI outperforms 54.69% of its industry peers.
In the last couple of years the Gross Margin of HITI has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.3% | ||
| PM (TTM) | N/A | ||
| GM | 25.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.25%
GM growth 5Y-5.48%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), HITI is destroying value.
HITI has more shares outstanding than it did 1 year ago.
The number of shares outstanding for HITI has been increased compared to 5 years ago.
HITI has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 3.31 indicates that HITI is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.31, HITI is in the better half of the industry, outperforming 70.83% of the companies in the same industry.
The Debt to FCF ratio of HITI is 4.08, which is a neutral value as it means it would take HITI, 4.08 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of HITI (4.08) is better than 85.94% of its industry peers.
A Debt/Equity ratio of 0.43 indicates that HITI is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.43, HITI is in line with its industry, outperforming 40.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.43 | ||
| Debt/FCF | 4.08 | ||
| Altman-Z | 3.31 |
ROIC/WACC0.64
WACC7.9%
2.3 Liquidity
HITI has a Current Ratio of 1.85. This is a normal value and indicates that HITI is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of HITI (1.85) is worse than 62.50% of its industry peers.
HITI has a Quick Ratio of 1.29. This is a normal value and indicates that HITI is financially healthy and should not expect problems in meeting its short term obligations.
HITI's Quick ratio of 1.29 is on the low side compared to the rest of the industry. HITI is outperformed by 67.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.85 | ||
| Quick Ratio | 1.29 |
3. Growth
3.1 Past
HITI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -328.07%.
HITI shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.18%.
The Revenue has been growing by 75.59% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-328.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)11.18%
Revenue growth 3Y42.34%
Revenue growth 5Y75.59%
Sales Q2Q%13.67%
3.2 Future
HITI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 74.44% yearly.
The Revenue is expected to grow by 15.53% on average over the next years. This is quite good.
EPS Next Y-12.22%
EPS Next 2Y104.72%
EPS Next 3Y96.71%
EPS Next 5Y74.44%
Revenue Next Year13.75%
Revenue Next 2Y21.31%
Revenue Next 3Y17.79%
Revenue Next 5Y15.53%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
HITI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 30.81, HITI can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, HITI is valued a bit cheaper than 72.92% of the companies in the same industry.
HITI is valuated rather expensively when we compare the Price/Forward Earnings ratio to 22.35, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 30.81 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, HITI is valued cheaply inside the industry as 85.94% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of HITI indicates a rather cheap valuation: HITI is cheaper than 83.85% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.83 | ||
| EV/EBITDA | 10.69 |
4.3 Compensation for Growth
HITI's earnings are expected to grow with 96.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y104.72%
EPS Next 3Y96.71%
5. Dividend
5.1 Amount
No dividends for HITI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
3.01
+0.01 (+0.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners6.97%
Inst Owner Change-1.97%
Ins Owners8.32%
Ins Owner ChangeN/A
Market Cap262.56M
Revenue(TTM)568.25M
Net Income(TTM)-9797000
Analysts80
Price Target5.3 (76.08%)
Short Float %5.26%
Short Ratio4.05
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)194.66%
Min EPS beat(2)-8%
Max EPS beat(2)397.33%
EPS beat(4)1
Avg EPS beat(4)15.55%
Min EPS beat(4)-315.76%
Max EPS beat(4)397.33%
EPS beat(8)5
Avg EPS beat(8)75.15%
EPS beat(12)9
Avg EPS beat(12)61.94%
EPS beat(16)12
Avg EPS beat(16)45.88%
Revenue beat(2)1
Avg Revenue beat(2)-0.2%
Min Revenue beat(2)-1.49%
Max Revenue beat(2)1.09%
Revenue beat(4)3
Avg Revenue beat(4)0.59%
Min Revenue beat(4)-1.49%
Max Revenue beat(4)1.6%
Revenue beat(8)5
Avg Revenue beat(8)0.02%
Revenue beat(12)9
Avg Revenue beat(12)1.49%
Revenue beat(16)13
Avg Revenue beat(16)7.4%
PT rev (1m)-6.59%
PT rev (3m)1.73%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-27.27%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)6.53%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 30.81 | ||
| P/S | 0.65 | ||
| P/FCF | 18.83 | ||
| P/OCF | 12.69 | ||
| P/B | 2.62 | ||
| P/tB | 7.14 | ||
| EV/EBITDA | 10.69 |
EPS(TTM)-0.09
EYN/A
EPS(NY)0.1
Fwd EY3.25%
FCF(TTM)0.16
FCFY5.31%
OCF(TTM)0.24
OCFY7.88%
SpS4.61
BVpS1.15
TBVpS0.42
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.76% | ||
| ROE | -6.93% | ||
| ROCE | 6.4% | ||
| ROIC | 5.06% | ||
| ROICexc | 7.36% | ||
| ROICexgc | 20.27% | ||
| OM | 2.3% | ||
| PM (TTM) | N/A | ||
| GM | 25.83% | ||
| FCFM | 3.47% |
ROA(3y)-14.91%
ROA(5y)-13.84%
ROE(3y)-26.27%
ROE(5y)-34.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.25%
GM growth 5Y-5.48%
F-Score5
Asset Turnover2.18
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.43 | ||
| Debt/FCF | 4.08 | ||
| Debt/EBITDA | 1.67 | ||
| Cap/Depr | 41.17% | ||
| Cap/Sales | 1.68% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 80.65% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.85 | ||
| Quick Ratio | 1.29 | ||
| Altman-Z | 3.31 |
F-Score5
WACC7.9%
ROIC/WACC0.64
Cap/Depr(3y)28.99%
Cap/Depr(5y)34.63%
Cap/Sales(3y)1.88%
Cap/Sales(5y)2.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-328.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-12.22%
EPS Next 2Y104.72%
EPS Next 3Y96.71%
EPS Next 5Y74.44%
Revenue 1Y (TTM)11.18%
Revenue growth 3Y42.34%
Revenue growth 5Y75.59%
Sales Q2Q%13.67%
Revenue Next Year13.75%
Revenue Next 2Y21.31%
Revenue Next 3Y17.79%
Revenue Next 5Y15.53%
EBIT growth 1Y2.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year418.19%
EBIT Next 3Y133.23%
EBIT Next 5Y81.08%
FCF growth 1Y38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.53%
OCF growth 3YN/A
OCF growth 5YN/A
HIGH TIDE INC / HITI FAQ
What is the fundamental rating for HITI stock?
ChartMill assigns a fundamental rating of 4 / 10 to HITI.
What is the valuation status of HIGH TIDE INC (HITI) stock?
ChartMill assigns a valuation rating of 4 / 10 to HIGH TIDE INC (HITI). This can be considered as Fairly Valued.
Can you provide the profitability details for HIGH TIDE INC?
HIGH TIDE INC (HITI) has a profitability rating of 3 / 10.
What is the financial health of HIGH TIDE INC (HITI) stock?
The financial health rating of HIGH TIDE INC (HITI) is 5 / 10.
Can you provide the expected EPS growth for HITI stock?
The Earnings per Share (EPS) of HIGH TIDE INC (HITI) is expected to decline by -12.22% in the next year.